Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | AKT1 | P31749 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CDC25A | P30304 | 1/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.69 |
| ▸ | PRKCG | P05129 | 1/20 | 0.69 |
| ▸ | PRKCB | P05771 | 1/20 | 0.69 |
| ▸ | PRKCA | P17252 | 1/20 | 0.69 |
| ▸ | PRKCH | P24723 | 1/20 | 0.69 |
| ▸ | PRKCI | P41743 | 1/20 | 0.69 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.69 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.69 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.69 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.69 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10415264 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| Miltefosine SCHEMBL20769827 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL4166195 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL596694 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| Miltefosine SCHEMBL26215 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| Tetradecylphosphocholine SCHEMBL5481590 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL29465558 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| Miltefosine SCHEMBL7189058 | 0.98 | LMNA (0.97) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL9234856 | 0.98 | LMNA (0.96) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL10934123 | 0.94 | LMNA (0.88) | LMNAAKT1ESR1ADORA3CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116055637-A | Method and system for detecting relation between signaling identification and link time slot control in network | 电信科学技术第五研究所有限公司 | 2023-05-02 | — | — | CN | claimed |
| CN-114262729-A | Cosmetic and method for testing soothing efficacy of raw materials of cosmetic | 广东悠质检测技术有限公司 | 2022-04-01 | — | — | CN | claimed |
| CN-106728445-A | Pharmaceutical composition of cure scapulohumeral periarthritis and preparation method thereof | 济南昊雨青田医药技术有限公司 | 2017-05-31 | — | — | CN | claimed |
| CN-101374805-A | Organic derivatives, their salts and use for the control of phytopathogens | ISAGRO SPA (IT) | 2009-02-25 | — | — | CN | claimed |
| CN-122057073-A | Preparation method of small-caliber artificial blood vessel of expanded polytetrafluoroethylene | 南通大学 | 2026-05-19 | — | — | CN | disclosed |
| CN-122055134-A | Methods and compositions for preventing or delaying skin aging and maintaining or improving skin condition | 南京纽邦生物科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4722352-A1 | AFRICAN SWINE FEVER VIRUS ASFV-KOR.INJE.MEC-01.2022 ATTENUATED BY CELL ADAPTATION, AND USE THEREOF | ChoongAng Vaccine Laboratories Co., Ltd (CAVAC) (KR) | 2026-04-08 | — | — | EP | disclosed |
| US-12595270-B2 | Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-20260034240-A1 | MULTIFUNCTIONAL CREAM HYDROGELS FOR POSTOPERATIVE ADHESION PREVENTION | UNIV NEBRASKA (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260035385-A1 | BENZO NITROGEN-CONTAINING HETEROAROMATIC RING DERIVATIVE AND USE THEREOF IN MEDICINE | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2026-02-05 | — | — | US | disclosed |
| US-12497434-B2 | IL-37 fusion proteins and uses thereof | HOFFMANN-LA ROCHE INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250376539-A1 | ANTI-C2 ANTIBODIES AND USES THEREOF | KIRA PHARMACEUTICALS SUZHOU LTD (CN) | 2025-12-11 | — | — | US | disclosed |
| US-20100286510-A1 | USE OF FLUORESCENT PHOSPHOLIPID ETHER COMPOUNDS IN BIOPSIES | CELL ACQUISITION CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100284929-A1 | FLUORESCENT IMAGING OF TUMORS USING PHOSPHOLIPID ETHER COMPOUNDS | CELL ACQUISITION CORP. | 2010-11-11 | — | — | US | disclosed |
| US-7811548-B1 | Fluorescent phospholipid ether compounds and compositions | CELLECTAR, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| CN-101374805-A | Organic derivatives, their salts and use for the control of phytopathogens | ISAGRO SPA (IT) | 2009-02-25 | — | — | CN | disclosed |
| CN-1426311-A | Medicament for stimulation of leucopoiesis and treatment of tumour and protozoan diseases acarinosis and arthropod-borne diseases and method for production thereof | MAX PLANCK GES ZUR FUEDERUNG D (DE) | 2003-06-25 | — | — | CN | disclosed |
| WO-1998024480-A1 | RADIOIODINATED PHOSPHOLIPID ETHER ANALOGS AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1998-06-11 | — | — | WO | disclosed |
| US-4935520-A | ANTITUMOR AND ANTICARCINOGENIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-06-19 | — | — | US | disclosed |
| EP-0108565-A2 | Phospholipids, their production and use thereof | Takeda Chemical Industries, Ltd. (JP) | 1984-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035385-A1 | BENZO NITROGEN-CONTAINING HETEROAROMATIC RING DERIVATIVE AND USE THEREOF IN MEDICINE | CYP2F1, CFH, CYP4F11 | LMNA 3313/4885AKT1 2567/4885ESR1 1819/4885 |
| US-20100286510-A1 | USE OF FLUORESCENT PHOSPHOLIPID ETHER COMPOUNDS IN BIOPSIES | PHOSPHO1, SGMS2, SGMS1 | LMNA 530/4885AKT1 4070/4885ESR1 1146/4885 |
| US-12595270-B2 | Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine | CYP2F1, CYP4F11, CFH | LMNA 3294/4885AKT1 2580/4885ESR1 1854/4885 |
| US-20260034240-A1 | MULTIFUNCTIONAL CREAM HYDROGELS FOR POSTOPERATIVE ADHESION PREVENTION | CDH1, EPCAM, ILK | LMNA 3059/4885AKT1 818/4885ESR1 2309/4885 |
| US-20100284929-A1 | FLUORESCENT IMAGING OF TUMORS USING PHOSPHOLIPID ETHER COMPOUNDS | PHOSPHO1, PEBP1, SGMS1 | LMNA 1413/4885AKT1 2443/4885ESR1 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.